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Abstract
An understanding of how the brain changes in chronic pain or responds to pharmacological or
other therapeutic interventions has been significantly changed as a result of developments in
neuroimaging of the CNS. These developments have occurred in 3 domains : (1) Anatomical Imaging
which has demonstrated changes in brain volume in chronic pain; (2) Functional Imaging (fMRI) that
has demonstrated an altered state in the brain in chronic pain conditions including back pain,
neuropathic pain, and complex regional pain syndromes. In addition the response of the brain to
drugs has provided new insights into how these may modify normal and abnormal circuits (phMRI
or pharmacological MRI); (3) Chemical Imaging (Magnetic Resonance Spectroscopy or MRS) has
helped our understanding of measures of chemical changes in chronic pain. Taken together these
three domains have already changed the way in which we think of pain – it should now be
considered an altered brain state in which there may be altered functional connections or systems
and a state that has components of degenerative aspects of the CNS.
Background
Various technologies have been used in drug discovery
and evaluation including combinatorial chemistry, high
throughput screening, pharmacogenomics, and proteom-
ics. More recently, brain imaging has provided novel
insights into functional, anatomical, and chemical
changes in the human condition that allow us to define
new approaches that may assist current drug development
efforts [1,2].
A number of findings suggest that our approach to the
treatment of chronic pain (e.g., neuropathic pain, fibro-
myalgia) has been hampered by a lack of understanding
of changes that occur subsequent to the onset of the con-
dition at the level of the central nervous system (Figure 1).
Amongst these are:
(i) A 'ceiling effect' of current analgesics for chronic pain,
rarely exceeding a 30% efficacy level in controlled trials
[3] or as defined by numbers needed to treat (NNT) or
need to harm (NNH) [4].
(ii) Chronic pain may express itself as a consequence of
other conditions. For example, chronic pain may arise
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after the onset of depression, even in patients without a
prior pain history of depression [5].
(iii) Chronic pain patients are defined as 'difficult
patients' in that they often have neuropsychological
changes that include changes in affect and motivation or
changes in cognition, all of which rarely predate their pain
condition.
(iv) In some conditions such as complex regional pain
syndrome (CRPS), manifestations of dysautonomia,
movement disorders, and spreading pain (ipsilateral and
contralateral) are all indicative of complex secondary
changes in the CNS that follow a relatively trivial periph-
eral nerve injury [6].
(v) Chronic opioid therapy (e.g., methadone mainte-
nance) results in a hyperalgesic state in both experimental
and clinical pain scenarios [7] implying changes in central
processing (e.g., alterations in modulatory systems).
(vi) Opioids, arguably the closest approximation to an
ideal analgesic, fail to produce pain relief in all individu-
als, even at high doses. This implies the development of
'analgesic resistance', a consequence of complex changes
in neural systems in chronic pain that complicates the
utility of opioids for long term therapy [8].
Taken together, these clinical insights suggest a few impor-
tant points related to pharmacological treatment for
chronic pain. First, that pain therapy clearly still requires
further research to define a basic understanding of the
nature of the disease (particularly regarding CNS process-
ing) that will allow improved analgesic agents in the
human condition. Second, that single targets are probably
not 'ideal' analgesics given the complexity of the disease
affecting the peripheral and central nervous system. Third,
a strategy for treating pain is required, given that it is a
chronic disease with a dynamic process (e.g., evolution of
co-morbid phenotypes such as anxiety or depression) that
is not easily reversed in most patients, and alterations in
brain anatomy (e.g., cortical thickness) can arise as a con-
sequence of the disease. Recent insights gained from struc-
tural and functional imaging the central nervous system
(CNS) have provided the groundwork for a novel
approach to developing therapies for chronic pain.
Chronic pain is a multidimensional process that now
must be considered as a chronic degenerative disease not
only affecting sensory and emotional processing, but also
producing an altered brain state. Therapeutic interven-
tions should be reconsidered in this context. Several func-
tional (Figure 2), neurochemical, and structural changes
have now been defined in the CNS of humans using func-
tional, chemical, and structural (Figure 2, 3, 4) neuroim-
aging techniques. These changes not only provide novel
insights into the pathology of the disease but also oppor-
tunities for objective indices for therapeutic efficacy.
Functional changes
Imaging patients with chronic pain is challenging. Never-
theless, a number of research groups have reported signif-
icant changes in pain processing at a functional level
including allodynia, functional plasticity, and alterations
in basic processes in the brain and brainstem [9-13].
Many of these functional changes have been defined in
the context of evoked pain. More recently, basal pain lev-
els have been measured using other approaches, including
functional connectivity of how networks are coupled
together [14]. Measures of resting state networks have sig-
nificant implications in terms of understanding and
Summary of Changes in Neural Function following Nerve  Injury Figure 1
Summary of Changes in Neural Function following 
Nerve Injury. In the Normal State, such as the response to 
noxious heat (left panel), the pain system provides salient 
information on the nature of the stimulus, the context of the 
stimulus, and the emotional response to the stimulus. In the 
chronic pain state, for example after nerve injury (right 
panel), changes occur along the neural axis. In the peripheral 
nerve there may be loss of fibers (1), changes in function of 
neurons in the dorsal root ganglion (2), and alterations in the 
dorsal horn (3). In the central nervous system, there are 
changes in dorsal horn (non-afferent inputs) as well as 
changes in sensory processing (e.g., hyperalgesia (3 and 5)) 
and emotional processing (5). These changes also result in an 
alteration of descending modulatory influences (4) from a 
number of central nervous system structures (e.g., cingulate, 
frontal cortex, amygdala etc). The constellation of changes in 
peripheral and central nervous systems result in changes to 
the pain intensity during spontaneous and evoked pain, and 
emotional processing (e.g., altered reward or hedonic state) 
that may lead to changes in comorbid disease in chronic pain 
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Examples of CNS Functional Measures Figure 2
Examples of CNS Functional Measures. A. Schematic of cortical areas involved with pain processing. The highlighted 
areas summarize areas found active in previous functional imaging studies. Color-coding reflects the hypothesized role of each 
area in processing the different psychological dimensions of pain. Numbers in parentheses indicate the relative involvement of 
these areas during different temporal stages of the pain experience. Areas displayed include insula, anterior cingulate cortex 
(ACC), posterior cingulate cortex (PCC), primary somatosensory cortex (SI), secondary somatosensory cortex (SII), inferior 
parietal lobe (Inf. Par), dorsolateral prefrontal cortex (DLPFC), pre-motor cortex (Pre-Mot), orbitofrontal cortex (OFC), 
medial prefrontal cortex (Med. PFC), posterior insula (P. Ins), anterior insula (A. Ins), hippocampus (Hip), entorhinal cortex 
(Ento). [Reprinted with permission from Casey and Tran, 2006]. For examples of brainstem involvement in pain processing, 
please refer to Tracey and Iannetti ([52]). B. Example of fMRI responses to painful phasic thermal stimulation to the forehead in 
a cohort of 12 subjects. (Moulton et al., unpublished observations).
A. Brain areas functionally related to pain processing.
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defining the brain state in different chronic pain condi-
tions and the have potential to measure therapeutic effi-
cacy. Such resting state networks have been reported to be
consistent across healthy subjects [15] and altered with
drug use [16] or disease state [17].
Neurochemical Changes
Alterations in neurotransmitters have also been reported
in chronic pain patients using magnetic resonance spec-
troscopy (MRS) [18]. Such approaches have been applied
to migraine [19], back pain [20,21], and to spinal cord
injury [22]. The approach can be used to define neuronal
and axonal markers [23], including specific metabolites
such as glutamate, aspartate, glycine, and GABA. Further-
more, the use of 19F-NMR as a non-invasive probe allows
for measurements of pharmacokinetics of drugs at target
sites as well as changes in patient disease state [24]. Neu-
rochemical changes can define biomarkers that precede
structural changes.
Structural Changes
At a macroscopic level, a number of papers have indicated
changes in volume in brain regions in patients with
chronic neuropathic pain [25], CRPS [26], and fibromyal-
gia [27]. These last two papers have been seminal in trans-
forming our approach and thinking on chronic pain, since
these changes indicate the potential of chronic pain being
a neurodegenerative disease. At a microscopic level,
changes in dendritic spine density or alterations in neuro-
nal count have been observed in pain and stress [28]. Such
changes also have implications for the development of co-
morbid disease such as depression [29].
In chronic pain conditions, there is an altered internal
milieu as a result of external inputs, altered endogenous
processing, or both. Chronic pain resulting from physical
(e.g., surgery, trauma) or emotional (abuse, torture,
depression) events produce changes in gene function that
result in alterations in neural circuits, neural integrity, and
receptor function in the CNS. The result is the phenotypic
expression of spontaneous pain and increased sensitivity
to painful and normally non-painful stimuli (e.g., brush,
pressure, thermal). In addition, the condition is sensitive
to less obvious perturbations such as changes in baromet-
ric pressure, or exacerbated in generalized inflammatory
conditions such as the flu.
Current therapies – What they may tell us
In the past, many drug treatments have focused on the
peripheral nerve and dorsal horn. However, most drugs
used in chronic pain have CNS effects. These drugs fall
into three main categories: opioids, antidepressants, and
anticonvulsants. Though not developed for treating pain
Schematic Examples of CNS Structural Changes Figure 3
Schematic Examples of CNS Structural Changes. Red circles signify decreased gray matter density relative to controls. 
A. Subjects with chronic back pain show decreases in gray matter density in bilateral dorsolateral prefrontal cortex (DLPFC) 
and right anterior thalamus (adapted from [25]). B. Patients with fibromyalgia show decreases in cingulate cortex (CC), medial 
prefrontal cortex (Med. PFC), parahippocampal gyrus (PHG) and insula (adapted from [27]). 3-D surface renderings were cre-
ated using Freesurfer.








Example of chemical measures Figure 4
Example of chemical measures. The relative concentra-
tion of neurotransmitters, such as glutamate (Glu) and gly-
cine (Gly), can be measured using MRS. Here, an in vivo 
proton MRS spectrum focused on the thalamus is displayed 
in a patient with chronic pain.
Thalamus
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using a rational mechanistic approach, nearly all of these
drugs have been applied to chronic pain treatment. Even
in the case of the opioids, subtle effects occur as a result of
multiple subtypes of specific receptors (e.g., µ1, µ2 and
µ3) or as a result of actions at multiple opioids receptor
sites. In the case of antidepressants, the initial mechanism
of action on monoamine oxidase (MAO) inhibition has
been extended to possible inhibition of sodium channels
[30]. For the anticonvulsants, there has always been an
association with probable efficacy in chronic pain, dating
back to the use of carbamazepine in trigeminal neuralgia
[31]. Indeed, the cross domain therapeutic flow has been
very fruitful in many cases, of which gabapentin is proba-
bly the most well known. Most anticonvulsants have or
are also being tried as treatments for neuropathic pain
states. While mechanistic approaches (that require careful
evaluation of specific responses e.g., cold, heat, von Frey
etc) to novel therapies have significant appeal, in practice
these may be difficult to implement in busy clinical prac-
tice.
In nearly all cases, drugs used in neuropathic pain have
actions on the CNS. These actions are not well defined in
terms of specificity at the receptor/gene level or at specific
regions within the brain. In addition, in most, if not all
controlled trials drugs for chronic pain have a ceiling
effect in their efficacy of approximately 30%.
A new focus for therapy
What can we learn from our past? Few analgesics have
been designer drugs (e.g., triptans for migraine), and most
agents that have come into clinical use by serendipity, or
'parallelism' (e.g., many if not all anticonvulsants have a
role in neuropathic pain). Either we are targeting only a
small fraction of CNS processes in chronic pain dysfunc-
tion or we are not stopping a progressive underlying
degenerative process with the current therapies. With
respect to the first this may be considered in terms of sys-
tems function (e.g., emotional circuitry may be more
important than sensory systems), non-neuronal systems
involved in CNS function, or neural plasticity that contin-
ues to change over time. The latter feeds into the second
issue. If chronic pain produces brain matter loss in regions
of the brain (e.g., for example the dorsolateral prefrontal
cortex) with associated consequences in altered neural
function (e.g., cognitive, emotional), then our focus is
very different or should be enlarged. In this context, we
should now also be evaluating drugs that have better 'neu-
roprotective effects". The limited information from the
use of NMDA inhibitors that are currently available (e.g.,
ketamine, memantine, methadone – seems to have a
combined opioids/NMDA antagonist action) suggests
that this may be the issue at hand.
Unusual drugs (i.e., outside of the purview of opioids,
anticonvulsants, or antidepressants) provide novel
insights into the chronic pain condition. There are a
number of drugs candidates for chronic pain therapy that
are examples pharmacological agents outside of the
'standard' trio of medications. These include, amongst
others, toxins [32], antibiotics. ([33,34], neuroprotective
agents [35], glial-modulating agents [36,37], and centrally
acting cannabinoids [38]. Many of these have multiple
known actions – for example, neurotoxins have anti-con-
vulsant effects [39]; cannabinoid type drugs may have an
effect on cytokine modulation ([40], on reward pathways
[41], or they may be neuroprotective [42].
Two pharmacological models provide significant insights
into the treatment of chronic pain: (i) drug induced
changes in central sensitization in an experimental model
of pain and (ii) the use of a novel therapy based on neu-
rochemical and neurodegenerative changes in chronic
pain.
Modulation of central sensitization
Central sensitization is observed following experimental
tissue injury and in clinical conditions such as inflamma-
tion, neuropathic pain, migraine, and perhaps other
chronic pain conditions. One fMRI study evaluated the
effects of gabapentin on CNS activity evoked during noci-
ceptive mechanical stimulation of a zone of secondary
hyperalgesia induced by capsaicin, a model of central sen-
sitization that may parallel some aspects of neuropathic
pain [43]. The results indicated that the drug decreased
activation in the brainstem during central sensitization,
and also suppressed stimulus-induced deactivations with
central sensitization. Extrapolations of this type of
approach may provide standards for evaluating and com-
paring drugs in surrogate models of pain.
Neurochemical protectant
Neuroprotective qualities of a drug can be based on two
observations: (i) changes in grey matter volume in the pre-
frontal cortex and (ii) changes in NMDA concentrations
in the frontal regions. The N-methyl d-aspartate (NMDA)
antagonist d-cycloserine (also known as the FDA-
approved antibiotic, Seromycin) was found to produce a
long term decrease in neuropathic pain behavior in rats
[34]. The authors argue that the drug may remove mem-
ory traces of pain, based on changes in the prefrontal cor-
tex. This type of approach highlights some of the specific
insights garnered from neuroimaging.
The 'perfect' chronic pain drug – Targeting 
sensory, emotional, and neurodegenerative 
processes
Current evidence suggests that the perfect pharmacologi-
cal therapeutic approach would be to: (a) provide earlyMolecular Pain 2007, 3:25 http://www.molecularpain.com/content/3/1/25
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and prolonged pain relief; (b) have peripheral and central
effects; (c) have neuroprotective effects; (d) protect
against neurodegenerative effects; (d) enhance endog-
enous analgesic systems though receptor mediated or
other mechanisms; and (e) modulate cytokine/immune
responses. Such information may now be garnered from
neuroimaging approaches potentially helping clinical
development programs by enabling the objective evalua-
tion of candidate therapeutics in clinical trials.
Some drugs may actually have a number of these effects in
a single agent. Examination of cannabinoid action pro-
vides a useful example since it has a number of attributes
that make it a useful model as a 'pain drug', as it is: (a) an
endogenous mediator (e.g., endogenous receptors); (b)
analgesic [44]; (c) a neuroprotectant [45]; and (d) an
immune modulator [46,47].
The human condition is not a controlled experimental
condition. Unfortunately, many patients seek treatment
for pain many months or years after its onset. There are
two groups of patients that could benefit from early inter-
vention – diabetics and postoperative patients – who
together comprise a significant number of neuropathic
pain patients. Treating early with drugs that inhibit or
slow down a degenerative process associated with pain
may provide long-term effects. While there are patient
compliance issues since there may not be an immediate
benefit, current evidence suggests that the longer the pain
persists, the greater the level of alterations in chronic pain
patients.
Future considerations – Approaches based on 
new insights
While neuroimaging clearly is not a stand-alone answer to
improved pharmacotherapies for chronic pain, recent
developments have provided novel insights through stud-
ies of the human brain in vivo in health and disease. We
believe that the application of these insights will help
focus therapeutic approaches in clinical trials. Some of
these are discussed below.
Treatment Approaches
Drugs should target three basic processes (a) sensory cir-
cuits; (b) emotional circuits; and (c) neural degeneration.
Outcome measures would probably be temporally differ-
ent, with cumulative effects over time. In many ways, the
'Antidepressant Model' may be a useful example, in that
the therapeutic effect may only be observed after some
time. This may be particularly so with respect to modula-
tion of processes resulting in decreased gray matter vol-
ume. For example, the 'Alzheimer Model' has a number of
parallels; chronic low dose therapy over months would
need to be implemented to achieve stabilization or possi-
ble reversal of the condition. The three processes of
decreasing pain, enhancing the motivational/emotional
status of an individual with chronic pain, and the amelio-
ration of neurodegenerative effects are clearly closely
interlinked and benefits in one domain could theoreti-
cally affect another. Overall, the ideal intervention would
rekindle functional circuits that are directly affected, or
would recruit circuits that can take on new functions.
Multiple Drugs over Time
The notion that one drug may be useful as a single therapy
may need to be reconsidered in the light of changes in the
nervous system that take place in the chronic pain condi-
tion. The rationale for this may relate to considerations
beyond 'tachyphylaxis' (i.e., a decreased response with the
same repeated doses). including the modulation of genes
to induce receptor changes causing them respond differ-
ently to a particular drug. This effect has been observed
with opioid switching, where the potency of the replace-
ment opioid is greater than if started initially in the
patient [48]. These changes can now be evaluated in terms
of alterations in specific neural systems using either func-
tional imaging or spectroscopy, and clearly can be applied
to different drug interventions including combination
therapies.
Monitoring Progress with Functional, Anatomical or 
Chemical Scans
Currently there are no objective measures for pain,
though recent advances allow for the adoption of specific
MRI scans in the clinical domain that may help measure
changes in patients. Specifically and perhaps most impor-
tantly, such changes may preempt clinical change (e.g.,
the onset of neuropathic pain following injury). Having
said this, there is some evidence in the Alzheimer domain
that there may be improvement without any obvious
measurable changes using these approaches. Therapies
may slow progression or reverse processes that produce
anatomical changes. Functional scans may be able to define
some objective outcomes such as continued central sensi-
tization, responses to specific analgesia (e.g., drug infu-
sion), responses to experimental pain (e.g., thermal or
mechanical), or disease process and progress. Anatomical
Scans may provide information on anisotropy [49] or cor-
tical thickness [50]. Chemical Scans can define changes in
a number of neurotransmitters as a result of treatment
[51].
Duration of Trials
Most current pain trials last a relatively short time to deter-
mine the efficacy of a particular drug. Imaging has
changed our understanding that chronic pain is most
likely a disease that, if not treated appropriately, progres-
sively alters brain function. Given the nature of chronic
pain, data acquired during post-marketing would be use-
ful for assessing the long-term effects of drugs used forMolecular Pain 2007, 3:25 http://www.molecularpain.com/content/3/1/25
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chronic pain. The FDA has already implemented some
guidelines for post-marketing as a consequence of recent
side effect profiles of a number of agents, including some
used in pain.
Conclusion
The ability to evaluate functional, anatomical, and chem-
ical changes in the human brain has provided new
insights into the CNS processing of pain in the human
condition and also how drugs such as analgesics may
work [1]. With respect to the latter, the fact that many
analgesics do not provide excellent levels of pain relief
indicates that multiple processes are at play in the chronic
condition that need to be targeted by new pharmaocther-
apies. Some of these targets are unexpected, based on
insights garnered from neuroimaging and will almost cer-
tainly mould some of our thinking in defining new
approaches to discovering analgesics for chronic pain.
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